VivoSeq
Other

OSA

0

Pipeline Programs↗

9

Active Trials↗

8

Companies Involved↗

OSA is an early-stage landscape with 0 programs across 8 companies. The most active players are Mylan Pharmaceuticals Inc, UCB, Pfizer.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

0 programs

PreclinicalUCB logo

UCB

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

PreclinicalA

Aclaris Therapeutics, Inc.

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalU

UNION therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

48

clinical trials

Completed29 · 60%
Recruiting7 · 15%
Unknown status6 · 13%
Terminated2 · 4%
Withdrawn2 · 4%
Not yet recruiting1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

48 trials

Do Endotypes Predict Response and Sequelae in OSA Patients
Recruiting·UUniversity of California, San Diego·Phase 2·NCT04875364·200 enrolled
Viral Mucosal Reprogramming
Recruiting·TThe University of Texas Medical Branch, Galveston·Phase 2·NCT05331170·75 enrolled
The Hysterosalpingogram (HSG) Experience And Tubal Spasm (HEAT) Study
Recruiting·UUniversity of Oklahoma·Phase 1·NCT07226310·240 enrolled
Trazodone on OSA Endotypes
Recruiting·—·Phase 1/2·NCT06286189·18 enrolled
Immunological Mechanisms Underlying Mucosal IgE Responses
Recruiting·UUniversity Hospital, Ghent·N/A·NCT06234761·50 enrolled
Rescue Pharmacotherapy for OSA
Recruiting·—·Phase 1/2·NCT05293600·70 enrolled
Pharmacological Activation of HMN for OSA Aim 2
Recruiting·—·Phase 1/2·NCT03858751·16 enrolled
Impact of Patient Involvement in Alerts Management of Telemonitoring CPAP
Active, not recruiting·—·Preclinical·NCT05960175·556 enrolled
IPP Placement & Intracavernosal Block
Not yet recruiting·WWake Forest University Health Sciences·Phase 4·NCT07246642·100 enrolled
Vascular Effect of CIMICIFUGA RACEMOSA
Completed·FFederal University of Minas Gerais·N/A·NCT03786809·60 enrolled
A Pilot Dose Ranging Study of Spinosad Creme Rinse
Completed·PParaPRO LLC·Phase 2·NCT00858481·36 enrolled
A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers
Completed·Pfizer logoPfizer·Phase 1·NCT01789528·48 enrolled
A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa Nigra
Completed·AAclaris Therapeutics, Inc.·Phase 2·NCT03224598·39 enrolled
Prucalopride + Prucalopride Booster vs. Prucalopride + Picosalax Booster for the Colon Capsule
Completed·QQueen's University·Phase 3·NCT01864915·60 enrolled
Parallel-Arm Study to Compare AD109 to Placebo With Patients With OSA (SynAIRgy Study)
Completed·AApnimed·Phase 3·NCT05813275·646 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)